Tyme Technologies Inc (NASDAQ:TYME) CEO Steve Hoffman sold 17,986 shares of the business’s stock in a transaction dated Monday, February 12th. The stock was sold at an average price of $3.82, for a total value of $68,706.52. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.
Shares of Tyme Technologies Inc (NASDAQ TYME) traded down $0.24 during mid-day trading on Wednesday, reaching $3.41. The company’s stock had a trading volume of 193,036 shares, compared to its average volume of 168,856. Tyme Technologies Inc has a fifty-two week low of $2.14 and a fifty-two week high of $9.50. The stock has a market capitalization of $332.70, a P/E ratio of -21.47 and a beta of -0.59.
A number of hedge funds have recently modified their holdings of the business. BlueCrest Capital Management Ltd purchased a new stake in Tyme Technologies during the fourth quarter valued at approximately $247,000. Monashee Investment Management LLC purchased a new stake in Tyme Technologies during the fourth quarter valued at approximately $128,000. Wells Fargo & Company MN raised its position in Tyme Technologies by 923.9% during the fourth quarter. Wells Fargo & Company MN now owns 29,180 shares of the company’s stock valued at $186,000 after purchasing an additional 26,330 shares during the period. Finally, Franklin Street Advisors Inc. NC purchased a new stake in Tyme Technologies during the fourth quarter valued at approximately $198,000. Institutional investors and hedge funds own 2.45% of the company’s stock.
Tyme Technologies Company Profile
Tyme Technologies, Inc is a clinical-stage biotechnology company. The Company is focused on developing cancer therapeutics that is intended to be broadly effective across tumor types and have low toxicity profiles. The Company’s therapeutic approach is designed to take advantage of a cancer cell’s innate metabolic weaknesses to compromise its defenses, leading to cell death through oxidative stress and exposure to the body’s natural immune system.
Receive News & Ratings for Tyme Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tyme Technologies and related companies with MarketBeat.com's FREE daily email newsletter.